Spondyloarthritis & psoriatic arthritis
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study
Authors' conclusion
Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals.
Study context
- Population
- Patients ≥18 years with active psoriatic arthritis (PsA), symptoms for ≥6 monthsreceived treatment
- Participants
- 290 patients
- Comparison
- Zasocitinib 30 mg, 15 mg or 5 mg once daily vs placebo for 12 weeks
- Primary endpoint
- ACR20 response
- Follow-up
- Week 12
Methodological detailsphase 2b, multicentre, double-blind, placebo-controlled, multiple-dose, 4-week safety follow-up
- Phase 2b
- Multicentre
- Double-blind
- Placebo-controlled
- Multiple-dose
- 4-week safety follow-up
Primary result
As reported in the abstract
30 mg vs Placebo: P = 0.002 · 15 mg vs Placebo: P = 0.002
Secondary outcomes
| Outcome | 30 mg | 15 mg | Placebo | P value |
|---|---|---|---|---|
| ACR50 response · week 1230 mg vs Placebo | 26.4% | 26.7% | 9.7% | nominal P = .009 |
| ACR50 response · week 1215 mg vs Placebo | nominal P = .005 | |||
| ACR70 response · week 1230 mg vs Placebo | 13.9% | — not stated in the abstract | 5.6% | nominal P = .158 |
| PASI 75 response (≥3% body surface area at baseline) · week 1230 mg vs Placebo | 45.7% | — not stated in the abstract | 15.4% | nominal P = .002 |
| MDA · week 1230 mg vs Placebo | 29.2% | — not stated in the abstract | 12.5% | nominal P = .014 |
— not stated in the abstract
Original publication
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study. Ann Rheum Dis. Published 4 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →